Abstract:Background: Current tumor models face challenges in accurately replicating the intricate and dynamic conditions of the tumor microenvironment (TME), limiting predictions of drug efficacy in drug development and personalized treatment. Furthermore, the continuous and real-time observation of drug responses variations resulting from tumor heterogeneity poses challenges in existing models, including patient-derived organoids and animal models. To address these limitations, our study introduces a novel approach through a tumor-microenvironment-on-chip (TMoC) that combines 3D tissue cultivation and a circulation system, incorporating physiological gradients of oxygen and nutrients. Serving as a tool to faithfully replicate the intricate TME, TMoC facilitates highly accurate drug screening for enhanced therapeutic precision. Method: Based on organ-on-chip and microfluidic systems, our platform reconstructs the cellular heterogeneity of the TME using tumor tissue-dissociated cells in collagen I or Matrigel within a strip-shaped 3D cultivation space, enabling simple analysis of regional responses. A circulation system, powered by a peristaltic pump, aids medication and immune cell entry for combination immunotherapy assessment. Real-time apoptosis analysis via fluorescence microscopy and sample retrieval for in-depth analysis are enabled. In drug screening, TMoC results are compared with mouse model outcomes and medication records for various cancers and treatments. Result: TMoC reconstructed physiological-like gradients, including oxygen levels, and facilitated the infiltration of cytotoxic CD8+ T cells, providing a distinctive model for assessing the synergistic impact of immune checkpoint inhibitors and chemotherapy drugs. Additionally, tissues cultured in TMoC retained their original cellular composition. TMoC demonstrated efficacy in drug screening across various cancer models, including breast, pancreatic, and colorectal cancers. In clinical studies, tumor tissue-derived cells from patients were cultivated on the TMoC, and the treating results are subsequently compared with clinical outcomes. Whether in animal models or clinical cases, the drug screening outcomes of TMoC consistently aligned with in vivo drug responses. Conclusion: The TMoC offering a platform that modeling some complex characteristics of TME. With applications in drug screening and clinical studies, it shows promising correlations between TMoC and in vivo responses. Citation Format: Chiao-Min Lin, Hsaun-Yu Mu, Li-An Chu, Ya-Hui Lin, Ji Li, Chao-Yu Liu, Hsi-Chien Huang, Sheng-Liang Cheng, Tsung-Ying Lee, Hsin Mei Lee, Hsin-Min Chen, Yun-Jen Tsai, Tzu-Hung Hsiao, Kee-Ming Man, Yunching Chen, Jen-Huang Huang. Tumor-microenvironment-on-chip: an ex vivo drug screening platform enabling real-time observation of regional tumor responses during drug development and clinical treatments [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6771.

Tumor Microenvironment Based on Extracellular Matrix Hydrogels for On-Chip Drug Screening

Recent Advances in Microfluidic Technology and Applications for Anti-Cancer Drug Screening

3D Cell-Based Biosensor for Cell Viability and Drug Assessment by 3D Electric Cell/matrigel-Substrate Impedance Sensing.

Bioprinting of Novel 3D Tumor Array Chip for Drug Screening

A Novel Micro-Groove Impedance Sensor for 3D Cell Viability Monitoring and High-Throughput Drug Screening

Near-physiological Microenvironment Simulation on Chip to Evaluate Drug Resistance of Different Loci in Tumour Mass.

Drug cytotoxicity and signaling pathway analysis with three-dimensional tumor spheroids in a microwell-based microfluidic chip for drug screening.

Enhancement Structural and Signaling Microenvironment of Artificial Tumor Extracellular Matrix for Enhanced Drug Screening

Large-Scale Antitumor Screening Based on Heterotypic 3D Tumors Using an Integrated Microfluidic Platform.

Abstract 6771: Tumor-microenvironment-on-chip: an ex vivo drug screening platform enabling real-time observation of regional tumor responses during drug development and clinical treatments

On-chip hydrogel arrays individually encapsulating acoustic formed multicellular aggregates for high throughput drug testing.

Micro-scaffold array chip for upgrading cell-based high-throughput drug testing to 3D using benchtop equipment.

Engineering a Brain Cancer Chip for High-throughput Drug Screening

High Throughput Scaffold-Based 3D Micro-Tumor Array for Efficient Drug Screening and Chemosensitivity Testing.

Hierarchical Hydrogels with Ordered Micro-Nano Structures for Cancer-on-a-Chip Construction

Engineered liver-derived decellularized extracellular matrix-based three-dimensional tumor constructs for enhanced drug screening efficiency

Study on Development of Composite Hydrogels With Tunable Structures and Properties for Tumor-on-a-Chip Research

Bi-layer Blood Vessel Mimicking Microfluidic Platform for Antitumor Drug Screening Based on Co-Culturing 3D Tumor Spheroids and Endothelial Layers.

Micropatterned Coculture Platform for Screening Nerve-Related Anticancer Drugs

Microfluidics Enabled Bottom-Up Engineering of 3D Vascularized Tumor for Drug Discovery

Microengineering Methods for Cell-Based Microarrays and High-Throughput Drug-Screening Applications